LAURA DEBACCO: Open Payments
NPI 1386955748 · LEWISTON, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$537 in 21 payments from 10 companies in 2025. Trend: 2023 $497 · 2024 $614 · 2025 $537
Food & beverage: $537
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 5 | $186 |
| Astellas Pharma US Inc | 2 | $59 |
| MILLICENT US INC | 3 | $55 |
| Sumitomo Pharma America, Inc. | 2 | $47 |
| ABBVIE INC. | 2 | $46 |
| Exeltis, USA Inc. | 2 | $44 |
| Exact Sciences Corporation | 2 | $44 |
| Novo Nordisk Inc | 1 | $21 |
| MAYNE PHARMA COMMERCIAL LLC | 1 | $19 |
| Amgen Inc. | 1 | $16 |
Products named: ZEPBOUND, MOUNJARO, Veozah, LILETTA, SLYND, Cologuard Collection Kit, MYFEMBREE, GEMTESA.
Industry payments across NY — which companies pay providers there.
